Research programme: malaria therapeutics - Eisai/Medicines for Malaria Venture
Alternative Names: Antimalarials - Eisai/Medicines for Malaria Venture; GPI-biosynthesis inhibitors - Eisai/Medicines for Malaria Venture; GWT1 - Eisai/Medicines for Malaria Venture; Gwt1p inhibitors - Eisai/Medicines for Malaria VentureLatest Information Update: 07 Feb 2025
At a glance
- Originator Eisai Co Ltd; Medicines for Malaria Venture
- Developer Eisai Co Ltd; Kitasato Institute; National Institute of Advanced Industrial Science and Technology; Osaka University
- Class Antimalarials
- Mechanism of Action GWT1 protein inhibitors; Protein biosynthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Malaria
Most Recent Events
- 07 Feb 2025 Early research is ongoing in Japan
- 28 Jan 2021 No recent reports of development identified for research development in Malaria in Japan
- 28 Jan 2021 No recent reports of development identified for research development in Malaria in Switzerland